Date Title & Summary Additional Formats
May 13, 2021
Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies
Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges PRINCETON, N.J. , May 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of
May 6, 2021
Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance
PRINCETON, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021. Highlights: Revenue was $66.7 million , representing growth of 16% over the first quarter of 2020.
May 4, 2021
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier
First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, N.J. , May 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the
April 30, 2021
Certara to Present at the BofA Securities 2021 Virtual Health Care Conference
PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 30, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will be participating in the BofA Securities 2021 Virtual Health Care Conference . William Feehery , CEO, and Andrew Schemick , CFO, are scheduled to present on
April 22, 2021
Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021
PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 22, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the first quarter of 2021 after the market close on Thursday, May 6, 2021 .
March 29, 2021
Certara Announces Closing of Public Offering of Common Stock
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 29, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 11,500,000 shares of its common stock by certain existing stockholders at a public offering price of $25.00 per
March 24, 2021
Certara Announces Pricing of Public Offering of Common Stock
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 24, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (“the selling stockholders”) at a price to the
March 22, 2021
Certara Announces Proposed Public Offering of Common Stock
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 22, 2021-- Certara, Inc. (“Certara”), a global leader in biosimulation, today announced a proposed underwritten public offering of 17 million shares of its common stock being offered by selling stockholders. Additionally, the selling stockholders intend to
March 11, 2021
Certara Set to Join Russell 1000® Index
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 11, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000 ® Index, effective after the U.S. market open on March 22, 2021 , according to a preliminary list of quarterly IPO additions
March 4, 2021
Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance
Year-over-year 2020 revenue grew 17% to $243.5 million Raised $768.5 million in gross IPO proceeds for the Company and selling stockholders PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its preliminary results for
Displaying 1 - 10 of 14